Enlivex Ltd. (1BT.F)
Frankfurt · EUR · Healthcare · Biotechnology
€0.155 (+0.00%) as of
Key statistics
- Market cap
- 237.46k
- P/E (TTM)
- 0.00
- Forward P/E
- -0.10
- EPS (TTM)
- 6,732.2700
- Dividend yield
- 0.00%
- 52-week range
- 0.1550 – 244.8000
- Beta
- 1.41
- Profit margin
- 0.00%
- Volume
- 1.00
About Enlivex Ltd.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Ness Ziona, Israel
- Employees
- 34
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.